[Expression of p38MAPK in the hippocampal CA1 region of rats with Abeta25-35-induced Alzheimer disease].
OBJECTIVE
To investigate the changes of p38MAPK expression in a rat model of Alzheimer disease (AD).


METHODS
Seventy-two adult SD rats were randomized equally into 4 groups, and a single-dose injection of Abeta25-35 (dementia group), normal saline (saline group), SB203580 (inhibitor group), or DMSO (inhibitor control group) was administered into the lateral cerebral ventricle. Y-maze tast was performed to evaluate the behavioral changes of the rats after the injections, and on days 4, 7 and 14 after the injection, p38MAPK expression in the hippocampal CA1 area was measured by means of immunohistochemistry.


RESULTS
On days 7 and 14 following Abeta25-35 injection, the training times, error number and total reaction time were significantly higher in dementia group than in saline group (P<0.05), but all these indices were significantly lowered in the inhibitor group as compared with the dementia group (P<0.05). Immunohistochemistry revealed obvious p38 expression in the dementia group 4 days after Abeta25-35 injection, which increased significantly with the passage of time (P<0.01). The gray scale in the inhibitor group was significantly higher than that in the dementia group (P<0.01).


CONCLUSIONS
p38MAPK activation in the hippocampal CA1 area is an event that persists during the entire course of Abeta25-35-induced AD in rats, and the inhibitor SB203580 prevents p38MAPK expression and improves the learning and memory abilities of the rats.
Zhang
Gui-lian
GL
Department of Neurology, Second Affiliated Hospital, Xi'an Jiaotong University College of Medicine, Xi'an 710004, China. zhgl_2006@126.com
Yao
Li
L
DU
Yun
Y
Zhang
Ru
R
Bu
Ning
N
Liu
Jing-jie
JJ
Yuan
Hai-feng
HF
Wu
Hai-qin
HQ
D000544:Alzheimer Disease / Q000139:chemically induced / Q000201:enzymology* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000008:administration & dosage / Q000633:toxicity; D000818:Animals; D006624:Hippocampus / Q000187:drug effects / Q000201:enzymology*; D007150:Immunohistochemistry; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D010446:Peptide Fragments / Q000008:administration & dosage / Q000633:toxicity; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D048051:p38 Mitogen-Activated Protein Kinases / Q000096:biosynthesis*
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C074636:amyloid beta-protein (25-35); D048051:p38 Mitogen-Activated Protein Kinases